Key result
Cardiovascular imaging and medications are generally safe in pregnancy and lactation with individualized, multidisciplinary care.
Why the study?
Cardiovascular disease in pregnancy is rising, yet under-representation of women of child-bearing potential in research has left knowledge gaps regarding diagnostic and therapeutic safety.
Provides essential guidance for clinicians on the safe use of cardiovascular imaging and medications in the complex and under-researched population of pregnant women.
Supports multidisciplinary risk-benefit decisions in pregnancy; leaves open need for prospective trials to confirm safety.
The prevalence of cardiovascular disease (CVD) in pregnancy, both diagnosed and previously unknown, is rising and a leading cause of maternal morbidity and mortality. Historically, women of child-bearing potential have been under-represented in research leading to lasting knowledge gaps in the cardiovascular care of pregnant and lactating women. Despite these limitations, clinicians should be familiar with the safety of frequently used diagnostic and therapeutic interventions to adequately care for this at-risk population. This document, the fourth of a five-part series, provides evidence-based recommendations regarding the use of common cardiovascular diagnostic tests and medications in pregnant and lactating women.
No takes yet. Share an insight, caveat, or question.
Bello et al. (2021) conducted a review in Cardiovascular disease in pregnancy. Diagnostic cardiovascular imaging and medications was evaluated. Diagnostic cardiovascular imaging and therapeutic medications can be safely used in pregnant and lactating women when guided by individualized risk-benefit assessments and multidisciplinary care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: